Cargando…
A recurrent ovarian cancer patient with a history of nine prior chemotherapy regimens who was safely treated with weekly paclitaxel plus bevacizumab and achieved a complete response: a case report
Herein, we describe our experience with a recurrent ovarian cancer patient who was treated safely with bevacizumab and who achieved a complete response despite receiving nine prior chemotherapy regimens. The patient was a 54-year-old woman with stage IIIC recurrent ovarian serous adenocarcinoma (gra...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4540113/ https://www.ncbi.nlm.nih.gov/pubmed/26316778 http://dx.doi.org/10.2147/OTT.S80143 |
_version_ | 1782386196831272960 |
---|---|
author | Takatori, Eriko Shoji, Tadahiro Nagasawa, Takayuki Takeuchi, Satoshi Hosoyachi, Akira Sugiyama, Toru |
author_facet | Takatori, Eriko Shoji, Tadahiro Nagasawa, Takayuki Takeuchi, Satoshi Hosoyachi, Akira Sugiyama, Toru |
author_sort | Takatori, Eriko |
collection | PubMed |
description | Herein, we describe our experience with a recurrent ovarian cancer patient who was treated safely with bevacizumab and who achieved a complete response despite receiving nine prior chemotherapy regimens. The patient was a 54-year-old woman with stage IIIC recurrent ovarian serous adenocarcinoma (grade 3). Computed tomography (CT) revealed that no evidence of ascites, multiple intraperitoneal dissemination, or intrapelvic lymph node metastases was present. The absence of bowel obstruction and disseminated lesions involving the intestinal tract was confirmed by CT. Performance status was 0, and a blood test also indicated preservation of major organ function. In our hospital, weekly paclitaxel plus bevacizumab therapy (paclitaxel at 80 mg/m(2) on days 1, 8, and 15; bevacizumab at 15/mg/kg on day 1 and every 21 days thereafter) was started. Eight cycles were administered, with no signs of gastrointestinal perforation, and the antitumor effect was evaluated as a complete response. The observed adverse events included grade 1 hyponatremia and grade 1 hypochloremia, and there was one grade 1 sensory peripheral neuropathy. These adverse events neither delayed treatment nor necessitated any dosage reductions. This case suggests that bevacizumab can be safely administered even to patients with recurrent ovarian cancer who have received three or more prior chemotherapy regimens if there are neither symptoms of bowel obstruction nor lesions suggestive of intestinal invasion on diagnostic imaging. |
format | Online Article Text |
id | pubmed-4540113 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-45401132015-08-27 A recurrent ovarian cancer patient with a history of nine prior chemotherapy regimens who was safely treated with weekly paclitaxel plus bevacizumab and achieved a complete response: a case report Takatori, Eriko Shoji, Tadahiro Nagasawa, Takayuki Takeuchi, Satoshi Hosoyachi, Akira Sugiyama, Toru Onco Targets Ther Case Report Herein, we describe our experience with a recurrent ovarian cancer patient who was treated safely with bevacizumab and who achieved a complete response despite receiving nine prior chemotherapy regimens. The patient was a 54-year-old woman with stage IIIC recurrent ovarian serous adenocarcinoma (grade 3). Computed tomography (CT) revealed that no evidence of ascites, multiple intraperitoneal dissemination, or intrapelvic lymph node metastases was present. The absence of bowel obstruction and disseminated lesions involving the intestinal tract was confirmed by CT. Performance status was 0, and a blood test also indicated preservation of major organ function. In our hospital, weekly paclitaxel plus bevacizumab therapy (paclitaxel at 80 mg/m(2) on days 1, 8, and 15; bevacizumab at 15/mg/kg on day 1 and every 21 days thereafter) was started. Eight cycles were administered, with no signs of gastrointestinal perforation, and the antitumor effect was evaluated as a complete response. The observed adverse events included grade 1 hyponatremia and grade 1 hypochloremia, and there was one grade 1 sensory peripheral neuropathy. These adverse events neither delayed treatment nor necessitated any dosage reductions. This case suggests that bevacizumab can be safely administered even to patients with recurrent ovarian cancer who have received three or more prior chemotherapy regimens if there are neither symptoms of bowel obstruction nor lesions suggestive of intestinal invasion on diagnostic imaging. Dove Medical Press 2015-08-11 /pmc/articles/PMC4540113/ /pubmed/26316778 http://dx.doi.org/10.2147/OTT.S80143 Text en © 2015 Takatori et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Case Report Takatori, Eriko Shoji, Tadahiro Nagasawa, Takayuki Takeuchi, Satoshi Hosoyachi, Akira Sugiyama, Toru A recurrent ovarian cancer patient with a history of nine prior chemotherapy regimens who was safely treated with weekly paclitaxel plus bevacizumab and achieved a complete response: a case report |
title | A recurrent ovarian cancer patient with a history of nine prior chemotherapy regimens who was safely treated with weekly paclitaxel plus bevacizumab and achieved a complete response: a case report |
title_full | A recurrent ovarian cancer patient with a history of nine prior chemotherapy regimens who was safely treated with weekly paclitaxel plus bevacizumab and achieved a complete response: a case report |
title_fullStr | A recurrent ovarian cancer patient with a history of nine prior chemotherapy regimens who was safely treated with weekly paclitaxel plus bevacizumab and achieved a complete response: a case report |
title_full_unstemmed | A recurrent ovarian cancer patient with a history of nine prior chemotherapy regimens who was safely treated with weekly paclitaxel plus bevacizumab and achieved a complete response: a case report |
title_short | A recurrent ovarian cancer patient with a history of nine prior chemotherapy regimens who was safely treated with weekly paclitaxel plus bevacizumab and achieved a complete response: a case report |
title_sort | recurrent ovarian cancer patient with a history of nine prior chemotherapy regimens who was safely treated with weekly paclitaxel plus bevacizumab and achieved a complete response: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4540113/ https://www.ncbi.nlm.nih.gov/pubmed/26316778 http://dx.doi.org/10.2147/OTT.S80143 |
work_keys_str_mv | AT takatorieriko arecurrentovariancancerpatientwithahistoryofninepriorchemotherapyregimenswhowassafelytreatedwithweeklypaclitaxelplusbevacizumabandachievedacompleteresponseacasereport AT shojitadahiro arecurrentovariancancerpatientwithahistoryofninepriorchemotherapyregimenswhowassafelytreatedwithweeklypaclitaxelplusbevacizumabandachievedacompleteresponseacasereport AT nagasawatakayuki arecurrentovariancancerpatientwithahistoryofninepriorchemotherapyregimenswhowassafelytreatedwithweeklypaclitaxelplusbevacizumabandachievedacompleteresponseacasereport AT takeuchisatoshi arecurrentovariancancerpatientwithahistoryofninepriorchemotherapyregimenswhowassafelytreatedwithweeklypaclitaxelplusbevacizumabandachievedacompleteresponseacasereport AT hosoyachiakira arecurrentovariancancerpatientwithahistoryofninepriorchemotherapyregimenswhowassafelytreatedwithweeklypaclitaxelplusbevacizumabandachievedacompleteresponseacasereport AT sugiyamatoru arecurrentovariancancerpatientwithahistoryofninepriorchemotherapyregimenswhowassafelytreatedwithweeklypaclitaxelplusbevacizumabandachievedacompleteresponseacasereport AT takatorieriko recurrentovariancancerpatientwithahistoryofninepriorchemotherapyregimenswhowassafelytreatedwithweeklypaclitaxelplusbevacizumabandachievedacompleteresponseacasereport AT shojitadahiro recurrentovariancancerpatientwithahistoryofninepriorchemotherapyregimenswhowassafelytreatedwithweeklypaclitaxelplusbevacizumabandachievedacompleteresponseacasereport AT nagasawatakayuki recurrentovariancancerpatientwithahistoryofninepriorchemotherapyregimenswhowassafelytreatedwithweeklypaclitaxelplusbevacizumabandachievedacompleteresponseacasereport AT takeuchisatoshi recurrentovariancancerpatientwithahistoryofninepriorchemotherapyregimenswhowassafelytreatedwithweeklypaclitaxelplusbevacizumabandachievedacompleteresponseacasereport AT hosoyachiakira recurrentovariancancerpatientwithahistoryofninepriorchemotherapyregimenswhowassafelytreatedwithweeklypaclitaxelplusbevacizumabandachievedacompleteresponseacasereport AT sugiyamatoru recurrentovariancancerpatientwithahistoryofninepriorchemotherapyregimenswhowassafelytreatedwithweeklypaclitaxelplusbevacizumabandachievedacompleteresponseacasereport |